Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 11 / 16 / 2019

Articles

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a

ORIGINAL ARTICLE

A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a

Xinyue Chen#,1, Qianguo Mao#,2, Yao Xie#,3, Xiaoguang Dou4, Qing Xie5, Jifang Sheng6, Zhiliang Gao7, Xiaoling Zhou8, Yingxia Liu9, Huanwei Zheng10, Shuqin Zhang11, Shibo Li12, Fusheng Zhu13, Yuqin Xu14, Mingxiang Zhang15, Yaoren Hu16, Xiaoping Chen17, Yan Huang18, Hong Ren*,19 and Jidong Jia*,20

1International Medicine Ward, Beijing YouAn Hospital, Capital Medical University, Beijing, China
2Department of Infectious Diseases, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, China
3Department of Liver Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China
4Department of Infectious Diseases, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
5Department of Infectious Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6Department of Infectious Diseases, The First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
7Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
8Department of Gastroenterology, Liuzhou Traditional Chinese Medical Hospital, Liuzhou, Guangxi, China
9Department of Infectious Diseases, Shenzhen Third People’s Hospital, Shenzhen, Guangdong, China
10Department of Infectious Diseases, The Fifth Hospital of Shijiazhuang, Shijiazhuang, Hebei, China
11Department of Infectious Diseases, Hepatology Hospital of Jilin Province, Changchun, Jilin, China
12Department of Infectious Diseases, Zhoushan Hospital of Zhejiang Province, Zhoushan, Zhejiang, China
13Department of Infectious Diseases, General Hospital of Dagang Oilfield, Tianjin, China
14Department of Infectious Diseases, The 211 Hospital of People’s Liberation Army, Harbin, Heilongjiang, China
15Department of Integrated Traditional and Western Medicine on Liver Diseases, The Sixth People’s Hospital of Shenyang, Shenyang, Liaoning, China
16Department of Liver Disease, Ningbo No. 2 Hospital of Zhejiang Province, Ningbo, Zhejiang, China
17Department of Infectious Diseases, Guangdong General Hospital, Guangzhou, Guangdong, China
18Department of Medical Science, Shanghai Roche Pharmaceuticals Ltd., Shanghai, China
19Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
20Department of Liver Disease, Beijing Friendship Hospital, Capital Medical University, Beijing, China
#These authors contributed equally to this study.
*Correspondence to: Hong Ren, Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, No. 76, Linjiang Road, Yuzhong District, Chongqing 400010, China. Tel: +86-13983888786, Fax: +86-23-63711527, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; Jidong Jia, Department of Liver Disease, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong’an Road, Xicheng District, Beijing 100069, China. Tel: +86-13501378269, Fax: +86-10-62704289, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2019;7(3):249-257 DOI: 10.14218/JCTH.2019.00016
Received: April 4, 2019 Accepted: July 19, 2019 Published online: August 20, 2019

Abstract

Background and Aims: Data are limited on the use of pegylated-interferon alpha-2a (peg-IFNα) in Chinese patients with chronic hepatitis B virus (HBV) infection (CHB). We evaluated the effectiveness and safety of peg-IFNα in Chinese patients with hepatitis B envelope antigen-negative CHB in routine clinical practice.

Methods: In this prospective, multicenter, observational, non-interventional cohort study, patients were assessed for up to 1 year after peg-IFNα treatment cessation. Treating physicians established the dosing and treatment duration according to Chinese clinical practice. Effectiveness of peg-IFNα treatment was measured by the percentage of: patients with HBV DNA <2000 IU/mL and loss of hepatitis B surface antigen (commonly known as HBsAg); HBV DNA level at end of treatment (EOT), and 6 months and 1 year posttreatment; and time course change in quantitative HBV DNA and HBsAg.

Results: At EOT, 6 months posttreatment, and 1 year posttreatment, the percentage of patients with HBV DNA <2000 IU/mL was 90.0%, 81.8%, and 82.2%, and that of patients with HBsAg loss was 6.5%, 9.4%, and 9.5%, respectively. The HBV DNA level decreased from 5.61 log IU/mL at baseline to 2.48 log IU/mL at EOT and 2.67 log IU/mL at 1 year posttreatment. The HBsAg level decreased from 3.08 log IU/mL at baseline to 2.24 log IU/mL at EOT and 2.10 log IU/mL at 1 year posttreatment. The incidence of adverse events was 52.0%.

Conclusions: Peg-IFNα has the potential to provide functional cure (HBsAg loss) for CHB and is well tolerated in hepatitis B envelope antigen-negative CHB patients in routine clinical practice in China.

Clinical Trial Registration: ClinicalTrials.gov (NCT01730508).

Keywords

Chronic hepatitis B, Prospective studies, Observational study, Interferon alpha

 

 

 

 

Journal of Clinical and Translational Hepatology 2019 vol. 7, 249-257  [ Html ] [ PDF Full-text ]

© The Authors 2019. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home